ジカウイルス治療薬の世界市場レポート 2025年

ジカウイルス治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で406億4,000万米ドルに成長します。予測期間中の成長は、臨床試験導入の増加、ジカ熱流行地域における治療薬需要の増加、研究開発投資の拡大、定性的診断のための血清検査キットの入手可能性、代替プログラムの拡大などに起因すると考えられます。予測期間における主な動向としては、抗ウイルス薬開発における技術進歩、血清学的検査の開発、モノクローナル抗体技術の革新、新規治療法の出現、迅速診断技術の進歩などが挙げられます。

感染率の増加がジカウイルス治療薬市場の拡大を牽引すると予想されます。感染率とは、特定の期間に集団内で疾病が伝播する可能性を指します。ジカ熱の感染率が上昇している背景には、不十分な媒介蚊の駆除、蚊の繁殖を促進する環境条件、感染地域における予防ヘルスケアへのアクセスの制限などがあります。この感染症の急増は、効果的なジカウイルス治療薬に対する需要を生み出し、増大する公衆衛生の脅威を緩和するためのワクチンや治療への投資を促します。例えば、2024年12月、英国の政府機関である英国健康安全保障局は、2024年1月から6月にかけて、ジカウイルスの感染者が8件確認されたと報告しました。その結果、感染率の上昇がジカウイルス治療薬市場を促進すると予想されています。

ジカウイルス治療薬市場の主要企業は、免疫反応を改善し、有効性を高め、予防効果をより長く持続させるために、第2世代アジュバント不活化ワクチンなどの革新的なワクチン技術を進めています。第2世代アジュバント不活化ワクチンは、不活化ウイルスと免疫増強アジュバントを組み合わせ、感染に対する身体の免疫防御を強化します。例えば、2024年3月、ワクチン製造を専門とするフランスのバイオテクノロジー企業であるバルネバSEは、VLA1601の第1相臨床試験を開始しました。この高純度不活化ワクチン候補はジカウイルス（ZIKV）を標的としており、バルネバがライセンス供与を受けている日本脳炎ワクチンIXIAROと同じ製造プラットフォームを使って開発されています。このワクチンは、有効性を高めるために重要な免疫反応を高めるアジュバントが配合されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ジカウイルス治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のジカウイルス治療薬市場：成長率分析
• 世界のジカウイルス治療薬市場の実績：規模と成長, 2019-2024
• 世界のジカウイルス治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ジカウイルス治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のジカウイルス治療薬市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アセトアミノフェン
• その他の非ステロイド性抗炎症薬（NSAID）
• 世界のジカウイルス治療薬市場ワクチンの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ワクチン
• サブユニットワクチン
• 生弱毒化ワクチン
• その他のワクチンの種類
• 世界のジカウイルス治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界のジカウイルス治療薬市場アセトアミノフェンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 経口懸濁液
• 静脈内製剤
• 世界のジカウイルス治療薬市場、その他の非ステロイド性抗炎症薬（NSAIDs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イブプロフェン
• アスピリン
• ナプロキセン
• セレコキシブ

第7章 地域別・国別分析

• 世界のジカウイルス治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のジカウイルス治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ジカウイルス治療薬市場：競合情勢
• ジカウイルス治療薬市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Moderna Inc.
• DiaSorin S.p.A.
• Emergent BioSolutions Inc.
• ARUP Laboratories
• Valneva SE
• Bharat Biotech International Limited
• Euroimmun AG
• Tiangen Biotech Co. Ltd.
• Creative Diagnostics
• Inovio Pharmaceuticals Inc.
• GeoVax Labs Inc.
• Moleculin Biotech Inc.
• BioVaxys Technology Corp.
• Kimer Med Limited
• LumiQuick Diagnostics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ジカウイルス治療薬市場2029：新たな機会を提供する国
• ジカウイルス治療薬市場2029：新たな機会を提供するセグメント
• ジカウイルス治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Zika virus therapeutics refer to medical treatments, drugs, or therapies designed to prevent or manage Zika virus infection, which is primarily transmitted through mosquito bites and can cause symptoms such as fever, rash, and joint pain. Treatment for Zika virus is mainly supportive, focusing on symptom relief, hydration, and monitoring for severe complications, including congenital Zika syndrome in newborns.

The primary product types for Zika virus therapeutics include acetaminophen and other non-steroidal anti-inflammatory drugs (NSAIDs). Acetaminophen is a commonly used pain reliever and fever reducer for managing mild to moderate pain and fever. These therapeutics are classified based on vaccine type, including inactivated vaccines, subunit vaccines, live-attenuated vaccines, and other vaccine types. They are administered in various healthcare settings, such as hospitals, clinics, and other medical facilities.

The zika virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides zika virus therapeutics market statistics, including the zika virus therapeutics industry global market size, regional shares, competitors with the zika virus therapeutics market share, detailed zika virus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the zika virus therapeutics industry. This zika virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The zika virus therapeutics market size has grown strongly in recent years. It will grow from $30.22 billion in 2024 to $32.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to the high incidence rate of infection, the disease burden of Zika virus and its associated comorbidities, the increasing demand for preventive measures, the rising significance of public health campaigns, and the expansion of global health initiatives.

The zika virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $40.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to the rising adoption of clinical trials, increasing demand for therapeutics in Zika-endemic regions, greater investment in R&D, the availability of serology kits for qualitative diagnosis, and the expansion of alternative programs. Key trends in the forecast period include technological advancements in antiviral drug development, the development of serological testing, innovations in monoclonal antibody technology, the emergence of novel therapies, and progress in rapid diagnostic technologies.

The increasing infection rates are expected to drive the expansion of the Zika virus therapeutics market. Infection rates refer to the likelihood of disease transmission within a population over a specific period. The rising incidence of Zika infections is driven by inadequate vector control, environmental conditions that promote mosquito breeding, and limited access to preventive healthcare in affected regions. This surge in infections creates a demand for effective Zika virus therapeutics, prompting investment in vaccines and treatments to mitigate the growing public health threat. For example, in December 2024, the UK Health Security Agency, a UK-based government organization, reported that between January and June 2024, there were eight confirmed cases of the Zika virus, a 700% increase compared to the same period in 2023. As a result, the rising infection rate is expected to propel the Zika virus therapeutics market.

Leading companies in the Zika virus therapeutics market are advancing innovative vaccine technologies, such as second-generation adjuvanted inactivated vaccines, to improve immune responses, enhance efficacy, and provide longer-lasting protection. Second-generation adjuvanted inactivated vaccines combine an inactivated virus with an immune-boosting adjuvant to strengthen the body's immune defense against infections. For instance, in March 2024, Valneva SE, a France-based biotechnology company specializing in vaccine production, initiated Phase 1 clinical trials for VLA1601. This highly purified inactivated vaccine candidate targets the Zika virus (ZIKV) and is developed using the same manufacturing platform as Valneva's licensed Japanese encephalitis vaccine, IXIARO. The vaccine is formulated with adjuvants to enhance immune response, which is critical for its effectiveness.

In September 2024, Indian Immunologicals, an India-based vaccine manufacturer, partnered with the Indian Council of Medical Research to develop a cost-effective Zika virus vaccine. This collaboration highlights the importance of creating affordable and accessible vaccines for emerging viral diseases, particularly Zika, which poses significant risks to pregnant women. The Indian Council of Medical Research is India's apex body for biomedical research, focusing on developing safe and effective vaccines to combat public health threats.

Major players in the zika virus therapeutics market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Moderna Inc., DiaSorin S.p.A., Emergent BioSolutions Inc., ARUP Laboratories, Valneva SE, Bharat Biotech International Limited, Euroimmun AG, Tiangen Biotech Co. Ltd., Creative Diagnostics, Inovio Pharmaceuticals Inc., GeoVax Labs Inc., Moleculin Biotech Inc., BioVaxys Technology Corp., Kimer Med Limited, LumiQuick Diagnostics Inc.

North America was the largest region in the zika virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in zika virus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zika virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The zika virus therapeutics market consists of sales of vaccines, antiviral drugs and antibody based therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Zika Virus Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on zika virus therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for zika virus therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The zika virus therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Acetaminophen; Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 2) By Vaccine Type: Inactivated Vaccine; Subunit Vaccine; Live-Attenuated Vaccine; Other Vaccine Types
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Acetaminophen: Oral Tablets; Oral Suspensions; Intravenous Formulations
• 2) By Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Aspirin; Naproxen; Celecoxib
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Zika Virus Therapeutics Market Characteristics

3. Zika Virus Therapeutics Market Trends And Strategies

4. Zika Virus Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Zika Virus Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Zika Virus Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Zika Virus Therapeutics Market Growth Rate Analysis
• 5.4. Global Zika Virus Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Zika Virus Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Zika Virus Therapeutics Total Addressable Market (TAM)

6. Zika Virus Therapeutics Market Segmentation

• 6.1. Global Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acetaminophen
• Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.2. Global Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccine
• Subunit Vaccine
• Live-Attenuated Vaccine
• Other Vaccine Types
• 6.3. Global Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global Zika Virus Therapeutics Market, Sub-Segmentation Of Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Oral Suspensions
• Intravenous Formulations
• 6.5. Global Zika Virus Therapeutics Market, Sub-Segmentation Of Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Aspirin
• Naproxen
• Celecoxib

7. Zika Virus Therapeutics Market Regional And Country Analysis

• 7.1. Global Zika Virus Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Zika Virus Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Zika Virus Therapeutics Market

• 8.1. Asia-Pacific Zika Virus Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Zika Virus Therapeutics Market

• 9.1. China Zika Virus Therapeutics Market Overview
• 9.2. China Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Zika Virus Therapeutics Market

• 10.1. India Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Zika Virus Therapeutics Market

• 11.1. Japan Zika Virus Therapeutics Market Overview
• 11.2. Japan Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Zika Virus Therapeutics Market

• 12.1. Australia Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Zika Virus Therapeutics Market

• 13.1. Indonesia Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Zika Virus Therapeutics Market

• 14.1. South Korea Zika Virus Therapeutics Market Overview
• 14.2. South Korea Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Zika Virus Therapeutics Market

• 15.1. Western Europe Zika Virus Therapeutics Market Overview
• 15.2. Western Europe Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Zika Virus Therapeutics Market

• 16.1. UK Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Zika Virus Therapeutics Market

• 17.1. Germany Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Zika Virus Therapeutics Market

• 18.1. France Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Zika Virus Therapeutics Market

• 19.1. Italy Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Zika Virus Therapeutics Market

• 20.1. Spain Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Zika Virus Therapeutics Market

• 21.1. Eastern Europe Zika Virus Therapeutics Market Overview
• 21.2. Eastern Europe Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Zika Virus Therapeutics Market

• 22.1. Russia Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Zika Virus Therapeutics Market

• 23.1. North America Zika Virus Therapeutics Market Overview
• 23.2. North America Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Zika Virus Therapeutics Market

• 24.1. USA Zika Virus Therapeutics Market Overview
• 24.2. USA Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Zika Virus Therapeutics Market

• 25.1. Canada Zika Virus Therapeutics Market Overview
• 25.2. Canada Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Zika Virus Therapeutics Market

• 26.1. South America Zika Virus Therapeutics Market Overview
• 26.2. South America Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Zika Virus Therapeutics Market

• 27.1. Brazil Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Zika Virus Therapeutics Market

• 28.1. Middle East Zika Virus Therapeutics Market Overview
• 28.2. Middle East Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Zika Virus Therapeutics Market

• 29.1. Africa Zika Virus Therapeutics Market Overview
• 29.2. Africa Zika Virus Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Zika Virus Therapeutics Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Zika Virus Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Zika Virus Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Zika Virus Therapeutics Market Competitive Landscape
• 30.2. Zika Virus Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Zika Virus Therapeutics Market Other Major And Innovative Companies

• 31.1. Moderna Inc.
• 31.2. DiaSorin S.p.A.
• 31.3. Emergent BioSolutions Inc.
• 31.4. ARUP Laboratories
• 31.5. Valneva SE
• 31.6. Bharat Biotech International Limited
• 31.7. Euroimmun AG
• 31.8. Tiangen Biotech Co. Ltd.
• 31.9. Creative Diagnostics
• 31.10. Inovio Pharmaceuticals Inc.
• 31.11. GeoVax Labs Inc.
• 31.12. Moleculin Biotech Inc.
• 31.13. BioVaxys Technology Corp.
• 31.14. Kimer Med Limited
• 31.15. LumiQuick Diagnostics Inc.

32. Global Zika Virus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Zika Virus Therapeutics Market

34. Recent Developments In The Zika Virus Therapeutics Market

35. Zika Virus Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Zika Virus Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Zika Virus Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Zika Virus Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer